Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T cell receptor mimic antibodies for cancer therapy
Leonid Dubrovsky, Tao Dao, Ron S. Gejman, et al.
OncoImmunology (2015) Vol. 5, Iss. 1, pp. e1049803-e1049803
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Emerging new therapeutic antibody derivatives for cancer treatment
Shijie Jin, Yanping Sun, Liang Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 321
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 66
Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains
Daniel T. Harris, Marlies V. Hager, Sheena N. Smith, et al.
The Journal of Immunology (2017) Vol. 200, Iss. 3, pp. 1088-1100
Open Access | Times Cited: 151
Targets and Antibody Formats for Immunotherapy of Neuroblastoma
Jeong A Park, Nai‐Kong V. Cheung
Journal of Clinical Oncology (2020) Vol. 38, Iss. 16, pp. 1836-1848
Open Access | Times Cited: 106
Therapeutic Antibodies against Intracellular Tumor Antigens
Iva Trenevska, Demin Li, Alison H. Banham
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 103
Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
Xinbo Yang, Daisuke Nishimiya, Sara Löchte, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 7, pp. 932-943
Open Access | Times Cited: 38
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
Aaron Y. Chang, Tao Dao, Ron S. Gejman, et al.
Journal of Clinical Investigation (2017) Vol. 127, Iss. 7, pp. 2705-2718
Open Access | Times Cited: 79
Comparative Analysis of the CDR Loops of Antigen Receptors
Wing Ki Wong, Jinwoo Leem, Charlotte M. Deane
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 65
Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
Markus Löffler, Daniel J. Kowalewski, Linus Backert, et al.
Cancer Research (2018) Vol. 78, Iss. 16, pp. 4627-4641
Open Access | Times Cited: 62
CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia
Guozhu Xie, Nikola A. Ivica, Bin Jia, et al.
Nature Biomedical Engineering (2020) Vol. 5, Iss. 5, pp. 399-413
Open Access | Times Cited: 60
TCR-like antibodies in cancer immunotherapy
Qinghua He, Zhaoyu Liu, Zhihua Liu, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 58
Emerging trends and therapeutic applications of monoclonal antibodies
M. Janaki Ramaiah, Hari P. Nalluri, Prakash Narayana Reddy, et al.
Gene (2024) Vol. 925, pp. 148607-148607
Closed Access | Times Cited: 7
TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies
Mahiuddin Ahmed, Andrés López‐Albaitero, Dmitry Pankov, et al.
JCI Insight (2018) Vol. 3, Iss. 4
Open Access | Times Cited: 42
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
Hardik Mody, K. OGASAWARA, Xu Zhu, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 3, pp. 530-557
Closed Access | Times Cited: 10
The application of antibody-based agents in cancer therapy based on their mechanisms of action
Kewen Qian, Guangyao Li, Shuyi Zhang, et al.
Fundamental Research (2024)
Open Access | Times Cited: 3
T-Cell Receptor CDR3 Loop Conformations in Solution Shift the Relative Vα-Vβ Domain Distributions
Monica L. Fernández‐Quintero, Nancy D. Pomarici, Johannes R. Loeffler, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 26
Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers
Xueyin Wang, Mark L. Sandberg, Aaron D. Martin, et al.
Journal of Immunotherapy (2021) Vol. 44, Iss. 8, pp. 292-306
Open Access | Times Cited: 21
The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic
Sylvia Annabel Dass, Venugopal Balakrishnan, Norsyahida Arifin, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets
Devin B. Lowe, Camille K. Bivens, Alexis S Mobley, et al.
mAbs (2017) Vol. 9, Iss. 4, pp. 603-614
Open Access | Times Cited: 25
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy
Angel Charles, Christopher M. Bourne, Tanya Korontsvit, et al.
OncoImmunology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 20
Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen
Xu Han, Agnes E. Hamburger, Jee‐Young Mock, et al.
Molecular Immunology (2020) Vol. 126, pp. 56-64
Closed Access | Times Cited: 17
Effects of HLA single chain trimer design on peptide presentation and stability
Kathryn A. K. Finton, Peter B. Rupert, Della Friend, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Opportunities and Challenges for Antibodies against Intracellular Antigens
Xiaofeng Yang, Shenxia Xie, Xiaomei Yang, et al.
Theranostics (2019) Vol. 9, Iss. 25, pp. 7792-7806
Open Access | Times Cited: 17
T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins
Yixiang Xu, Georgina To’a Salazar, Ningyan Zhang, et al.
Antibody Therapeutics (2019) Vol. 2, Iss. 1, pp. 22-32
Open Access | Times Cited: 16
Re-examination of MAGE-A3 as a T-cell Therapeutic Target
Aaron D. Martin, Xueyin Wang, Mark L. Sandberg, et al.
Journal of Immunotherapy (2020) Vol. 44, Iss. 3, pp. 95-105
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top